rs1800089
Variant summary
Our verdict is Likely pathogenic. Variant got 7 ACMG points: 7P and 0B. PM1PM2PM5PP3
The NM_000492.4(CFTR):c.1399C>T(p.Leu467Phe) variant causes a missense change. The variant allele was found at a frequency of 0.000025 in 1,601,010 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. L467P) has been classified as Pathogenic.
Frequency
Consequence
NM_000492.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_pathogenic. Variant got 7 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CFTR | NM_000492.4 | c.1399C>T | p.Leu467Phe | missense_variant | 11/27 | ENST00000003084.11 | NP_000483.3 | |
CFTR-AS1 | NR_149084.1 | n.221+1263G>A | intron_variant |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CFTR | ENST00000003084.11 | c.1399C>T | p.Leu467Phe | missense_variant | 11/27 | 1 | NM_000492.4 | ENSP00000003084.6 |
Frequencies
GnomAD3 genomes AF: 0.0000592 AC: 9AN: 152118Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000398 AC: 10AN: 251216Hom.: 0 AF XY: 0.0000368 AC XY: 5AN XY: 135790
GnomAD4 exome AF: 0.0000214 AC: 31AN: 1448892Hom.: 0 Cov.: 28 AF XY: 0.0000194 AC XY: 14AN XY: 721796
GnomAD4 genome AF: 0.0000592 AC: 9AN: 152118Hom.: 0 Cov.: 32 AF XY: 0.0000673 AC XY: 5AN XY: 74318
ClinVar
Submissions by phenotype
Cystic fibrosis Pathogenic:3Uncertain:2Benign:3Other:1
Likely benign, criteria provided, single submitter | clinical testing | Ambry Genetics | Dec 22, 2017 | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
Likely pathogenic, criteria provided, single submitter | curation | Institute of Human Genetics, University of Leipzig Medical Center | Sep 05, 2022 | This variant was identified in 4 unrelated patients with a clinically confirmed diagnosis of cystic fibrosis. The variant was classified in the context of a project re-classifying variants in the German Cystic Fibrosis Registry (Muko.e.V.). Link: https://www.muko.info/angebote/qualitaetsmanagement/register/cf-einrichtungen/mukoweb. Criteria applied: PS3_SUP, PM2_SUP, PM3, PP3, PP4 - |
Likely benign, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Jul 22, 2021 | - - |
Likely benign, criteria provided, single submitter | clinical testing | Johns Hopkins Genomics, Johns Hopkins University | Aug 22, 2019 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Mendelics | Nov 05, 2018 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Baylor Genetics | Jun 04, 2020 | This variant was determined to be of uncertain significance according to ACMG Guidelines, 2015 [PMID:25741868]. - |
not provided, no classification provided | literature only | ClinVar Staff, National Center for Biotechnology Information (NCBI) | - | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Center for Genomic Medicine, King Faisal Specialist Hospital and Research Center | Mar 26, 2024 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 18, 2024 | This sequence change replaces leucine, which is neutral and non-polar, with phenylalanine, which is neutral and non-polar, at codon 467 of the CFTR protein (p.Leu467Phe). This variant is present in population databases (rs1800089, gnomAD 0.009%). This variant has been observed in several individuals affected with CFTR-related conditions (PMID: 16436643, 29271547, 21783433, 10923036, 26436105, 27917292, 24106596, 19202204, 29504914). However, in most of these individuals this variant was observed in cis with a pathogenic allele, which suggests that this c.1399C>T variant was not the primary cause of disease. ClinVar contains an entry for this variant (Variation ID: 53246). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt CFTR protein function with a positive predictive value of 80%. Experimental studies have shown that this missense change affects CFTR function (PMID: 29271547). This variant disrupts the p.Leu467 amino acid residue in CFTR. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 20510657, 23891399, 23974870, 26708955). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
not provided Uncertain:3
Uncertain significance, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Mar 01, 2022 | CFTR: PS4:Moderate, PP4 - |
Uncertain significance, criteria provided, single submitter | clinical testing | Mayo Clinic Laboratories, Mayo Clinic | Jun 10, 2020 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Quest Diagnostics Nichols Institute San Juan Capistrano | Mar 16, 2021 | - - |
Bronchiectasis with or without elevated sweat chloride 1 Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Institute of Human Genetics, University of Leipzig Medical Center | Feb 15, 2024 | - - |
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Aug 20, 2024 | Variant summary: CFTR c.1399C>T (p.Leu467Phe) results in a non-conservative amino acid change located in the ABC transporter-like and AAA+ ATPase domain of the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 4e-05 in 251294 control chromosomes. This frequency is not significantly higher than estimated for a pathogenic variant in CFTR causing Cystic Fibrosis (4e-05 vs 0.013), allowing no conclusion about variant significance. c.1399C>T has been reported in the literature in individuals affected with Cystic Fibrosis as well as CFTR-related disorders, however, often a second allele is not specified. In addition, the variant has been reported in multiple patients in cis with the common pathogenic mutation F508del, in both internal samples and reported in the literature (e.g. Vecchio-Pagan_2016, Costa_2011, Sermet-Gaudelus_2010, Terlizzi_2020, Kondratyeva_2022), suggesting the variant may be benign. The variant has also been reported in an internal sample with two pathogenic mutations, providing additional supporting evidence for a benign role. However, recent cases and functional evidence has suggested that p.Leu467Phe, as part of a complex allele with F508del, may impact patient response to CFTR modulators, although it does not necessarily increase the severity of disease symptoms (Kondratyeva_2022, Sondo_2022). In a cell-based functional study, CFTR-p.Leu467Phe tested alone had a significantly reduced maturation compared to CFTR-WT and a reduced channel activity (Baatallah_2018). However, the impact of this variant in relation to human disease remains unclear. The following publications have been ascertained in the context of this evaluation (PMID: 20538955, 36286063, 32292813, 32026723, 32150665, 29271547, 27917292, 26436105, 28603918, 26437683, 36142302, 21783433, 22892530, 24106596, 22020151, 16436643, 19202204, 10923036, 18716917, 35328596, 38388235, 35365085). ClinVar contains an entry for this variant (Variation ID: 53246). Based on the evidence outlined above, the variant was classified as VUS-possibly benign. - |
CFTR-related disorder Uncertain:1
Uncertain significance, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Sep 23, 2024 | The CFTR c.1399C>T variant is predicted to result in the amino acid substitution p.Leu467Phe. This variant has been reported along with p.Phe508del in a non-affected individual (Sobczyriska-Tomaszewska et al. 2013. PubMed ID: 22892530). It has been reported in the heterozygous state in individuals with cystic fibrosis or cystic fibrosis related disorders, without indication of a second pathogenic variant (Elahi et al. 2006. PubMed ID: 16436643; Amato et al. 2011. PubMed ID: 22020151). This variant has been reported as a complex allele (variants in cis on the same allele) with p.Phe508del in individuals with cystic fibrosis. Some of these individuals the complex allele was present alone and in other cases p.Phe508del was found in trans on the other allele (Raraigh et al. 2021. PubMed ID: 34782259; Petrova et al. 2022. PubMed ID: 35365085). There was no difference in disease severity when comparing patients with the complex allele to those who were homozygous for p.Phe508del (Petrova et al. 2022. PubMed ID: 35365085). Minigene analysis using HEK293 cells showed this variant affects protein maturation and channel activity, and also demonstrated that p.Phe508del alone recovers with corrector/potentiator treatment; however, this same treatment was ineffective for the complex allele (Baatallah et al. 2018. PubMed ID: 29271547). An alternate nucleotide change affecting the same amino acid (p.Leu467Pro) has been reported to be pathogenic (Sosnay et al. 2013. PubMed ID: 23974870; Internal Data, PreventionGenetics). This variant is reported in 0.0085% of alleles in individuals of European (non-Finnish) descent in gnomAD. This variant has conflicting classifications in ClinVar ranging from likely benign to likely pathogenic (https://www.ncbi.nlm.nih.gov/clinvar/variation/53246/). At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at